reference/676078

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/676078

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	1662
issn	1387-2877 1875-8908
issueIdentifier	4
pageRange	1649-1662
publicationName	Journal of Alzheimer's disease : JAD
startingPage	1649
bibliographicCitation	Hannestad J, Duclos T, Chao W, Koborsi K, Klutzaritz V, Beck B, Patel AK, Scott J, Thein SG, Cummings JL, Kay G, Braithwaite S, Nikolich K. Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer's Disease: A Phase II Double-Blind Placebo-Controlled Trial. J Alzheimers Dis. 2021;81(4):1649–62. doi: 10.3233/jad-210011. PMID: 33967047.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5b9e44fb9e573f2f575a6d6186d83c0d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f1db01cbbcf053df73340fab608d5af7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_53d7f2afd686fe91b7321ccb5a395f6c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_70fe6772c010d9815ac6cb6acef69277 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_10dbc4e6afbe9762a175ec57bddc549e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_52cd8884c5cab63cc19f72ce164682a4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b7d601afcb6738260af52c85d19d2c4d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f68d85a583cb758263baec08d3b1cf33 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a9b67c40f3bd38a3ce8181314deaf4d4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_689b0142fb7dcf6275d837db2126f35a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f01bed2c510ba267c26d7c345dc491f3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_15d71fc14f319e2bdb32ec475ac7dc2f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_baa1c3e0a8628eb11479f813f0ac5b90
date	2021-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/33967047 https://doi.org/10.3233/jad-210011
isPartOf	https://portal.issn.org/resource/ISSN/1875-8908 https://portal.issn.org/resource/ISSN/1387-2877 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21942
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer’s Disease: A Phase II Double-Blind Placebo-Controlled Trial
discusses	http://id.nlm.nih.gov/mesh/M0028009
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D018697Q000009 http://id.nlm.nih.gov/mesh/D000544Q000188 http://id.nlm.nih.gov/mesh/D003071Q000187
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D000073216 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000544Q000523 http://id.nlm.nih.gov/mesh/D018697Q000627 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D018697Q000008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6852 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10435 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8135

Total number of triples: 52.